Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients

Inclusion Criteria: * Clinical diagnosis of T2DM * Treated with basal insulin for ≥ 6 months, with current dose stable for ≥ 6 weeks of ≥ 0.3 U/kg/day, with or without anti-hyperglycemic agents and in whom the Investigator feels advancement from basal to basal and bolus therapy is needed for the patient * A1C 7.5-11.0% by central lab value at screening visit * Already perform self-monitoring of blood glucose (SMBG) and willing to test blood glucose (BG) over the course of the study * Body Mass Index of ≤ 40 kg/m2 Exclusion Criteria: * Currently on or has been treated in the past year with insulin regimens that include bolus insulins except the need for insulins in the settings of acute illness or hospitalization * History of type 1 diabetes mellitus (T1DM), or diabetic ketoacidosis (DKA), or secondary forms of diabetes such as cystic fibrosis * Known hypersensitivity or allergy to insulin-glargine or its excipients or any other insulins * Two or more severe hypoglycemic episodes within the prior year * Hypoglycemia unawareness defined by history * History of proliferative diabetic retinopathy * Is currently unstable and/or has moderate-to-severe medical illness in the Investigator's judgment * Uncontrolled hypertension (either treated or untreated) defined as a systolic blood pressure ≥ 160 mmHg or a diastolic blood pressure ≥ 100 mmHg at screening * History of recent major surgery within 6 months, or minor surgery within 3 months (such as appendectomy) prior to screening visit, or a planned surgery during the study period * History of bariatric surgery * Active chronic infections * Women of child-bearing age who are pregnant, planning pregnancy, breast-feeding, or, if capable of pregnancy, are not practicing contraception if heterosexually active * Known hypersensitivity to plastics/polymers/adhesives * Known difficulties with adherence of adhesives, bandages, or dressings * Participated in any research study within the past 30 days * Currently participating in another investigational trial * Use of short term or chronic systemic steroids within three months of entry into the study or likelihood that same might be required during the conduct of the study